文献速递中医儿科中医内科中药与中成药合理使用

小儿风热清口服液对比奥司他韦治疗儿童流感的非劣效随机试验

Efficacy and safety of Xiao'er Fengre Qing oral liquid versus Oseltamivir in treating pediatric influenza (wind-heat invading the defense syndrome): a multicenter, randomized, non-inferiority trial.
PubMed 文献 · Front Pharmacol · 2025-05-22

本研究为多中心、随机、双盲双模拟、阳性药对照的非劣效试验,纳入418例风热犯卫证流感患儿,比较小儿风热清口服液与奥司他韦的疗效与安全性。结果显示两组临床恢复时间中位数均为3天,风险比1.115(95%CI 0.912-1.363),非劣效成立;退热时间、并发症等指标两组相当,安全性良好。

要点

  • 小儿风热清口服液治疗儿童流感临床恢复时间不劣于奥司他韦。
  • 两组完全退热时间中位数均为32小时,差异无统计学意义。
  • 痰兼证和食滞兼证疗效组间有显著差异,需辨证使用。

核心结论

  • 小儿风热清口服液治疗儿童流感(风热犯卫证)在临床恢复时间上不劣于奥司他韦。
  • 其退热、症状缓解、并发症及重症发生率、对乙酰氨基酚使用和病毒转阴率与奥司他韦相当,且安全性良好。

研究设计与样本

  • 多中心、区组随机、双盲双模拟、阳性药对照的非劣效临床试验,计划入组420例,实际纳入全分析集418例(试验组208例,对照组210例)。
  • 试验组给予小儿风热清口服液加奥司他韦颗粒模拟剂,对照组给予奥司他韦颗粒加小儿风热清口服液模拟剂,疗程5天,治疗后观察2天。

主要发现

  • 两组临床恢复时间中位数均为3天,风险比(试验组/对照组)为1.115(95%CI 0.912-1.363),非劣效检验成立。
  • 两组完全退热时间中位数均为32小时,差异无统计学意义(P=0.407)。
  • CARIFS症状维度评分随时间曲线下面积组间差异无统计学意义(P=0.211)。
  • 风热犯卫证疗效率和惊兼证疗效率组间差异无统计学意义(P=0.076,P=0.168),痰兼证和食滞兼证疗效率组间差异有统计学意义(P=0.008,P=0.024)。
  • 咽红肿、咳嗽、痰多或喉间痰鸣、食欲不振等症状消失率组间差异有统计学意义(P<0.05),其他症状无显著差异。

关键数值与推荐

  • 主要终点临床恢复时间非劣效界值未在摘要中报告。
  • 并发症及重症流感发生率、对乙酰氨基酚使用率、病毒转阴率组间差异均无统计学意义(P>0.05)。
  • 不良事件发生率(P=0.885)和不良反应发生率(P=0.685)组间差异无统计学意义。

临床怎么用

  • 对于儿童流感风热犯卫证,可考虑使用小儿风热清口服液作为奥司他韦的替代选择。
  • 辨证属痰兼证或食滞兼证时,小儿风热清口服液可能更具优势。

局限性

  • 摘要未报告非劣效界值、样本量计算依据及具体不良事件类型。
  • 研究仅针对风热犯卫证患儿,结论外推至其他证型需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Xiao'er Fengre Qing Oral Liquid (XFQOL) is developed based on the classical traditional Chinese medicinal formula Yinqiao Powder. Compared to the original formulation, XFQOL exhibits enhanced heat-clearing, detoxification, and fever reduction, which can effectively address the common complications associated with influenza in children and is well-suited for pediatric use. However, there is currently a lack of high-quality evidence from clinical trials to support its efficacy and safety in clinical applications. OBJECTIVE: This study aimed to investigate the efficacy and safety of XFQOL compared with Oseltamivir in pediatric influenza. METHODS: A multicenter, block-randomized, double-blind, double-dummy, positive-drug-controlled, non-Inferiority clinical trial design was conducted. The study plans to enroll 420 pediatric participants, with 210 in each group. The experimental group will receive XFQOL with an Oseltamivir granules placebo, and the control group will receive Oseltamivir granules with a XFQOL placebo for 5 days, followed by a 2-day post-treatment observation. The primary endpoint was clinical recovery time, while secondary endpoints included complete fever resolution time, the area under the curve (AUC) of Canadian Acute Respiratory Illness and Flu Scale (CARIFS) symptom dimension Score over time, Traditional Chinese Medicine (TCM) syndrome efficacy, disappearance rates for individual symptoms, incidences of complications and severe and critical influenza, the usage of acetaminophen, and viral negative conversion rate. Safety evaluation focused on adverse events (AE) and adverse drug reactions (ADR). RESULTS: A total of 418 participants were included in the Full Analysis Set, with 208 in the experimental group and 210 in the control group. Baseline characteristics were comparable between the groups. The median time to clinical recovery was 3 days for both groups, with a hazard ratio and its 95% confidence interval (experimental group/control group) of 1.115 (95% CI: 0.912-1.363). Non-inferiority testing demonstrated that the experimental group was not inferior to the control group. Subgroup analyses (positive for RT-PCR influenza, positive for RT-PCR influenza A, positive for RT-PCR influenza B) yielded results consistent with the primary endpoint. The median time to complete fever resolution was 32 h in both groups, with no statistically significant difference (P = 0.407). There were no statistically significant differences in the AUC of CARIFS symptom scores over time between the groups (P = 0.211). No significant differences were observed between the groups in the efficacy rates of TCM syndromes of Wind-Heat Invading the Defense Syndrome (P = 0.076) and Fright-complicated Syndrome (P = 0.168); however, significant differences were found in Phlegm-complicated Syndrome (P = 0.008) and Food-stagnation-complicated Syndrome (P = 0.024). The disappearance rates for individual symptoms, such as red and swollen pharynx, cough, copious sputum or audible phlegm sounds in the throat, and lack of appetite, showed statistically significant differences between the groups (P < 0.05), while no significant differences were observed for other symptoms. No statistically significant differences were observed between the experimental and control groups in the incidence of complications and severe and critical influenza, the usage of acetaminophen, and viral negative conversion rate (P > 0.05). The incidence rates of AE (P = 0.885) and ADR (P = 0.685) were comparable between the two groups, with no statistically significant differences observed. CONCLUSION: The efficacy of XFQOL in treating pediatric influenza (Wind-Heat Invading the Defense Syndrome) is non-inferior to Oseltamivir with respect to clinical recovery time. Additionally, its effectiveness in terms of fever reduction, symptom alleviation, incidences of complications and severe and critical influenza, the usage of acetaminophen, and viral negative conversion rate is comparable to that of Oseltamivir. Furthermore, it demonstrates good safety, suggesting its potential for clinical application. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov, identifier ChiCTR2300076191.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Guo S, Li X, Zheng Y, et al. Efficacy and safety of Xiao'er Fengre Qing oral liquid versus Oseltamivir in treating pediatric influenza (wind-heat invading the defense syndrome): a multicenter, randomized, non-inferiority trial. Front Pharmacol. 2025. PMID: 40474974. doi:10.3389/fphar.2025.1584003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。